Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication.

@article{Bihorac2014ValidationOC,
  title={Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication.},
  author={Azra Bihorac and Lakhmir S. Chawla and Andrew D. Shaw and Ali Khalil I. Al-Khafaji and Danielle L. Davison and George E Demuth and Robert Fitzgerald and Michelle N. Gong and Derrel D Graham and Kyle J. Gunnerson and Michael Heung and Saeed A. Jortani and Eric Kleerup and Jay L. Koyner and Kenneth E Krell and Jennifer L Letourneau and Matthew E. Lissauer and James J. Miner and H. B. Nguyen and Luis M. Ortega and Wesley H. Self and Richard Sellman and Jing Shi and Joely A. Straseski and James E. Szalados and Scott T. Wilber and Michael G. Walker and Jason Wilson and Richard G Wunderink and Janice M Zimmerman and John A. Kellum},
  journal={American journal of respiratory and critical care medicine},
  year={2014},
  volume={189 8},
  pages={932-9}
}
RATIONALE We recently reported two novel biomarkers for acute kidney injury (AKI), tissue inhibitor of metalloproteinases (TIMP)-2 and insulin-like growth factor binding protein 7 (IGFBP7), both related to G1 cell cycle arrest. OBJECTIVES We now validate a clinical test for urinary [TIMP-2]·[IGFBP7] at a high-sensitivity cutoff greater than 0.3 for AKI risk stratification in a diverse population of critically ill patients. METHODS We conducted a prospective multicenter study of 420… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 10 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 115 extracted citations

Similar Papers

Loading similar papers…